The protective effect of a Kampo medicine, Hochu-ekki-to (TJ-41) on experimental candidiasis in immunosuppressed mice was investigated. ICR mice were immunosuppressed by injection of prednisolone or cyclophosphamide, given TJ-41 orally and challenged intravenously with Candida albicans (day 0). Treatments with a daily dose of 1 g/kg/day of TJ-41 for 8 days from day-4 or for 4 days from day 0 significantly prolonged the life span of the Candida-infected mice pretreated with prednisolone. The latter treatment appeared to inhibit the colonization of Candida in kidneys of the infected mice. These results suggest that Hochu-ekki-to can be used as a therapeutic agent against candidiasis in patients with glucocorticoid-induced immunosuppression.
No takes yet. Share an insight, caveat, or question.
Abe et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: